Clinical impact of MR spectroscopy when MR imaging is indeterminate for pediatric brain tumors

被引:26
作者
Norfray, JF
Tomita, T
Byrd, SE
Ross, BD
Berger, PA
Miller, RS
机构
[1] Chicago Northside MRI Ctr, Chicago, IL 60657 USA
[2] Childrens Mem Hosp, Dept Pediat Neurosurg, Chicago, IL 60614 USA
[3] Childrens Mem Hosp, Dept Radiol, Chicago, IL 60614 USA
[4] Huntington Med Res Inst, Pasadena, CA 91105 USA
[5] Monsanto Co, St Louis, MO 63167 USA
[6] Amer Med Assoc, Dept Res & Data Anal, Chicago, IL 60610 USA
关键词
D O I
10.2214/ajr.173.1.10397111
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE, We undertook this study to determine if single-voxel proton (hydrogen) MR spectroscopy could have clinical impact on the management of pediatric brain tumors when MR findings were indeterminate. SUBJECTS AND METHODS. Eleven children (mean age, 9 years) being examined for brain tumors underwent MR imaging that revealed indeterminate criteria of enhancement, mass effect, and prolonged T1 and T2 signal. MR spectroscopy was then used to distinguish radiation necrosis from tumor in one patient, differentiate residual tumor from scarring in two patients, document early treatment response in three patients, and discriminate benign from malignant masses in five patients. RESULTS. In 10 of the II patients, spectra were successfully acquired. Based on the chemical analysis of the indeterminate area shown on MR imaging, clinical impact was achieved in these 10 patients. Clinical impact included treatment modification in five patients, follow-up studies replacing further treatment in three patients, and tumor characterization in the remaining two patients. Confirmation was by histology in four patients and by follow-up MR imaging and MR spectroscopy for up to 30 months in the remaining six patients. CONCLUSION. When MR imaging is indeterminate in evaluating pediatric brain tumors, MR spectroscopy can provide objective neurochemical information, thereby altering treatment.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 33 条
[1]   METABOLISM OF HUMAN GLIOMAS - ASSESSMENT WITH H-1 MR SPECTROSCOPY AND F-18 FLUORODEOXYGLUCOSE PET [J].
ALGER, JR ;
FRANK, JA ;
BIZZI, A ;
FULHAM, MJ ;
DESOUZA, BX ;
DUHANEY, MO ;
INSCOE, SW ;
BLACK, JL ;
VANZIJL, PCM ;
MOONEN, CTW ;
DICHIRO, G .
RADIOLOGY, 1990, 177 (03) :633-641
[2]   INOSITOL LIPIDS AND CELL-PROLIFERATION [J].
BERRIDGE, MJ .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 907 (01) :33-45
[3]   Brain stem involvement in children with neurofibromatosis Type 1: Role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma [J].
Broniscer, A ;
Gajjar, A ;
Bhargava, R ;
Langston, JW ;
Heideman, R ;
Jones, D ;
Kun, LE ;
Taylor, J .
NEUROSURGERY, 1997, 40 (02) :331-337
[4]   ON THE INTERPRETATION OF PROTON NMR-SPECTRA FROM BRAIN-TUMORS INVIVO AND INVITRO [J].
BRUHN, H ;
MICHAELIS, T ;
MERBOLDT, KD ;
HANICKE, W ;
GYNGELL, ML ;
HAMBURGER, C ;
FRAHM, J .
NMR IN BIOMEDICINE, 1992, 5 (05) :253-258
[5]  
Demaerel P, 1997, INT J NEURORADIOL, V3, P94
[6]  
DESTEFANO N, 1995, MAGN RESON MED, V34, P721
[7]   MAPPING OF BRAIN-TUMOR METABOLITES WITH PROTON MR SPECTROSCOPIC IMAGING - CLINICAL RELEVANCE [J].
FULHAM, MJ ;
BIZZI, A ;
DIETZ, MJ ;
SHIH, HHL ;
RAMAN, R ;
SOBERING, GS ;
FRANK, JA ;
DWYER, AJ ;
ALGER, JR ;
DICHIRO, G .
RADIOLOGY, 1992, 185 (03) :675-686
[8]   SHORT TE H-1 SPECTROSCOPIC MR-IMAGING OF NORMAL HUMAN BRAIN - REPRODUCIBILITY STUDIES [J].
JACKSON, EF ;
DOYLE, TJ ;
WOLINSKY, JS ;
NARAYANA, PA .
JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING, 1994, 4 (04) :545-551
[9]  
KORNBERG H, 1993, NEW ENCY BRITANNICA, V23, pN893
[10]   LOCALIZED H-1-NMR SPECTROSCOPY IN PATIENTS WITH CHRONIC HEPATIC-ENCEPHALOPATHY - ANALYSIS OF CHANGES IN CEREBRAL GLUTAMINE, CHOLINE AND INOSITOLS [J].
KREIS, R ;
FARROW, N ;
ROSS, BD .
NMR IN BIOMEDICINE, 1991, 4 (02) :109-116